National Psoriasis Foundation

Clinical Trials

Find a trial

Reasons to participate

  • Access to new treatments not available on the market.
  • Access to free medication.
  • Compensation for participating (in some trials).
  • Satisifcation in helping advance medical research.

Factors to consider

It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

The purpose of this study is to determine the relationship between two types of cell signals (type I IFN and TNF) in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.

Condition: Psoriasis | Phase: Phase 4 | Minimum Age: 18 Years

Learn more »

Safety and Efficacy of Secukinumab in Mild Psoriasis

Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti- interleukin (IL)-17A treatment, investigators may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.

Condition: Psoriasis | Phase: Phase 2 | Minimum Age: 18 Years

Learn more »

This Study is Being Conducted to Evaluate the Safety, Tolerability, and Efficacy of KD025 Administered Orally for 16 Weeks to Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for S

This study is being conducted to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis.

Condition: Psoriasis | Phase: Phase 2 | Minimum Age: 18 Years

Learn more »

Biologics Anchoring Study

Biologics are used to treat conditions such as moderate-to-severe psoriasis, a chronic condition that impairs quality of life as much or more than other major medical conditions. Biopharmaceuticals are medications which are are isolated from biological sources including microorganisms, animals or humans. These medications generally function to decrease inflammation or disrupt the inflammatory cycle. Patients are often apprehensive about choosing a biologic medication over other options due to anxiety regarding the need for regular injections, leaving the patient undertreated and continuing to suffer with psoriasis. Reducing fears of injections may improve adherence to treatment and may improve treatment outcomes. Fear of injection is inherently subjective and may be easily modified. Anchoring is the tendency for humans to rely on a specific value when making decisions and to make judgments relative to that value. Patients who have never taken an injection will subjectively view the idea of taking an injection relative to the "not taking any injection" baseline. This comparison is scary and represents a considerable hurdle to taking a new injectable medication that may be otherwise optimal for their treatment. Resetting the anchor may be all that is needed to help patients overcome fear of injection. The objective is to assess whether patients offered a once monthly injectable biologic would be more likely to accept that biologic medication if they are first counseled about a daily injection.

Condition: Moderate-to-severe Psoriasis | Phase: N/A | Minimum Age: 18 Years

Learn more »

DFD01 Spray vs. Comp01 Lotion HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

This study evaluates the potential of HPA suppression in adolescent patients with moderate to severe plaque psoriasis when using DFD01 Spray (twice daily for either 15 or 29 days) vs. Comp01 Lotion (twice daily for 15 days).

Condition: Plaque Psoriasis | Phase: Phase 3 | Minimum Age: 12 Years

Learn more »

Get the latest research news and tips on managing your psoriasis and psoriatic arthritis.